David Wright

David Wright

Auto-generated profile, based on publicly available information

David Wright

Respiratory and Immunology Biometrics and Statistical Innovation, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 March 2025 in Pharmaceutical Statistics
Verified
Journal Article
Closed access
JBJames Bell
James Bell
TDThomas Drury
Thomas Drury
TMTobias Mütze
Tobias Mütze
CPChristian Pipper
Christian Pipper
LGLorenzo Guizzaro
Lorenzo Guizzaro
DWDavid Wright
David Wright

25 November 2024 in British Journal of Clinical Pharmacology
Verified
Journal Article
Open access
HLHelle Lynggaard
Helle Lynggaard
SMSue McKendrick
Sue McKendrick
MBMark Baird
Mark Baird
EKEssam Kerwash
Essam Kerwash
VLVivian Lanius
Vivian Lanius
DWDavid Wright
David Wright
The International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use has published an addendum on estimands and sensitivity analysis in clinical trials along with related training materials. These define an estimand as a precise description of the treatment effect that reflects the scientific question of interest. In December 2022, the US Food and Drug Administration released draft guidance recommending estimands of interest be specified in bioequivalence trial protocols. However, experience in implementing estimands in clinical pharmacology trials is limited and so we introduce estimands and provide step‐by‐step considerations about the estimand thinking process in this setting. We also describe a particular case study, a bioequivalence trial, illustrating how the estimand framework can provide transparency and alignment throughout the design, conduct and analysis of the trial. This involves discussion of how to identify and handle intercurrent events, which are events that can affect interpretation of the drug or metabolite endpoints. Furthermore, we discuss the broader applicability of the estimand framework to other clinical pharmacology trials. Finally, we encourage further discussion between industry, academia, regulators and the International Council for Harmonisation on whether the estimand framework should be considered in all clinical pharmacology regulatory guidance documents.

4 August 2026 in Clinical Trials
Verified
Journal Article
Open access
SBStef Baas
Stef Baas
LPLukas Pin
Lukas Pin
DRDavid S. Robertson
David S. Robertson
FBFrank Bretz
Frank Bretz
HCHearn Jay Cho
Hearn Jay Cho
SVSofia S. Villar
Sofia S. Villar
Background: Because confirmatory clinical trials are costly, large-scale endeavors, the choice of their design carries significant weight. While the current methodological landscape offers tools to address residual pre-trial uncertainty through prespecified adaptations to design elements, design choices remain frequently constrained by prevailing orthodoxies. Methods: We examine how unacknowledged design uncertainties (e.g., sample size calculations based on incorrect effect size or variance estimates) impact the statistical, ethical, and resource-stewardship goals of confirmatory trials. We contrast how fixed and adaptive design strategies handle these uncertainties, detailing the operational safeguards, firewalls, and trade-offs (e.g., complexity, operational bias) required to preserve trial integrity. Results: Strict adherence to default templates prevents stakeholders from matching the design strategy to the specific complexities of the research question. We observe that the gold standard status of fixed designs often obscures their limitations in handling design uncertainties. A rigid adherence to these conventions can ethically hinder a trial’s ability to deliver conclusive results. Conversely, while adaptive designs can offer tools to efficiently reduce uncertainty, we acknowledge that adaptive elements are not without cost; their implementation requires rigorous safeguards to manage specific risks to trial integrity and potential operational biases. Conclusion: To better align clinical research with its ethical and scientific mandates, we issue two calls to action. First, trial designers, including statisticians, must clearly articulate how target and design uncertainties impact ethical obligations, promoting an open-minded evaluation of both fixed and adaptive methods. Second, stakeholders must foreground ethical considerations during design selection, requiring explicit justification for the use—or non-use—of adaptive elements. The ethical path forward is not to default to the old or blindly adopt the new, but to explicitly justify the chosen design based on its responsiveness to the specific uncertainties of the trial. We posit that trial design must transition from a habit-based process to one where pre-trial uncertainties are openly discussed and addressed.